Navigation Links
Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
Date:5/6/2013

nfectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen Research & Development and Janssen Biotech are part of the Janssen Pharmaceutical Companies. Please visit http://www.janssenrnd.com for more information.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
9. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
10. Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax
11. CombiMatrix Corporation Selects Cartagenia BENCHlab CNV Platform to Bolster Expanded Lab Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 BioStructures, ... the American Association of Tissue Banks (AATB), it ... Chief Executive Officer. Accreditation follows an ... a specially trained AATB inspector.  It establishes that ... within the facility meets or exceeds the standards ...
(Date:9/30/2014)...  Proteomics is a focus point for investment ... Kalorama Information.  The healthcare market research publisher said that ... the past two years.  The activity ranges from ... companies and academic institutions, to deals between pharma ... Kalorama observed the industry in its report, ...
(Date:9/30/2014)... -- In a recent study it was ... the Eldor spinal needle 25G, 103 mm appeared significantly ... spinal needles of the same gauge and length of ... an excellent type of regional anesthesia for many operations ... It is estimated that 100 million patients worldwide ...
Breaking Medicine Technology:Biostructures, LLC Earns AATB Accreditation 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3
...  Results from the combined analysis of two European ... 3rd European Lung Cancer Conference in Geneva, Switzerland. ... samples from advanced non-squamous non-small cell lung cancer ... plus erlotinib.  Results showed that the VeriStrat test ...
... (NASDAQ: STAA ), the leading developer, manufacturer and ... that the total number of its Visian® ICL implants in ... have been the Visian Toric ICL which is approved in ... of the U.S. The Company will highlight the benefits of ...
Cached Medicine Technology:VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer 2VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer 3STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 2STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 3STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 4STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 5
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set ... Nashville, Tennessee. RMS welcomes the launch of an entirely ... of a new treatment center for the Lung Institute. ... Institute to Nashville, the hope is to bring awareness ... diagnosed and undiagnosed. With Nashville being a hub for ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Two revolutionary procedures ... treatment of gum disease a far less painful ... past. , “If you’ve ever felt electric shock waves surge ... sip a cold beverage, it’s possible you already know the ... who is a general dentist in West Palm Beach, and ...
(Date:9/30/2014)... (Sept. 30, 2014) Levothyroxine is considered the gold ... a new review of therapies for the condition ... altered that assessment, say a team of investigators.,1Their analysis, ... Thyroid , finds insufficient consistent data exist to ... generic, or sold under various trade names, such as ...
(Date:9/30/2014)... ANN ARBORThe discovery of a gene mutation that causes ... development of drugs that block the rapid, unstoppable cell ... at the University of Michigan and the U-M Health ... devastating disease dyskeratosis congenita, in which precious hematopoietic stem ... DC age prematurely and are prone to cancer and ...
(Date:9/30/2014)... Cleveland, Ohio (PRWEB) September 30, 2014 ... agreement which provides CHL access to Life Length’s proprietary ... most advanced and comprehensive telomere test on the market ... that reports the percentage of short telomeres, providing the ... Shay, Vice Chairman of the Department of Cell Biology ...
Breaking Medicine News(10 mins):Health News:Regenerative Medicine Solutions Expanding 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 2Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 3
... for treating age-related loss of strength, researchers say , ... exercised and received the growth hormone known as "mechano ... to a British study. , The results suggest that ... which causes increased fragility, said Dr. Geoff Goldspink of ...
... of psychiatric side effects, including suicidal thoughts, , WEDNESDAY, ... help people quit smoking, Chantix and Zyban, will now ... problems, including depression and suicidal thoughts, U.S. health officials ... Administration said it was mandating the black-box warnings, the ...
... ... of the journal Nature includes three companion papers describing the results of ... psychiatric disorder that affects up to 70 million people worldwide. The causes ... some individuals the current treatments work well. There are multiple factors that ...
... 1 Despite rapid advances using a child,s own cord ... due to injury or disease, most pregnant women today don,t ... According to research published in the Journal of Reproductive ... themselves only "minimally informed." , , (Logo: ...
... , OAKBROOK TERRACE, Ill., July 1 Dental Network ... its acquisition of DenteMax, an independent subsidiary of Blue ... providing and administering health benefits to members residing in ... reside outside the state. , , ...
... Give BCBSM Customers Expanded National Dental Network; Solidify BCBSM Position ... Mich., July 1 Blue Cross Blue Shield of Michigan ... been acquired by Dental Network of America, LLC (DNoA), a ... BCBSM and DNoA -- will provide BCBSM with a more ...
Cached Medicine News:Health News:Growth Hormone May Build Muscle in Older Men 2Health News:Anti-Smoking Drugs Get FDA 'Black-Box' Warning 2Health News:Anti-Smoking Drugs Get FDA 'Black-Box' Warning 3Health News:International Collaboration led by Dr. Pablo V. Gejman,Researcher At NorthShore University HealthSystem's Research Institute, Finds Genetic Association of Schizophrenia to Chromosome 6p Variant 2Health News:International Collaboration led by Dr. Pablo V. Gejman,Researcher At NorthShore University HealthSystem's Research Institute, Finds Genetic Association of Schizophrenia to Chromosome 6p Variant 3Health News:International Collaboration led by Dr. Pablo V. Gejman,Researcher At NorthShore University HealthSystem's Research Institute, Finds Genetic Association of Schizophrenia to Chromosome 6p Variant 4Health News:Cord Blood Awareness Month: Understanding Still Low, Despite Medical Advancements 2Health News:Cord Blood Awareness Month: Understanding Still Low, Despite Medical Advancements 3Health News:Cord Blood Awareness Month: Understanding Still Low, Despite Medical Advancements 4Health News:Dental Network of America (DNoA) Acquires DenteMax, Owned by Blue Cross Blue Shield of Michigan 2Health News:Dental Network of America (DNoA) Acquires DenteMax, Owned by Blue Cross Blue Shield of Michigan 3Health News:Dental Network of America (DNoA) Acquires DenteMax, Owned by Blue Cross Blue Shield of Michigan 4Health News:Blue Cross Blue Shield of Michigan-owned DenteMax Acquired by Dental Network of America 2Health News:Blue Cross Blue Shield of Michigan-owned DenteMax Acquired by Dental Network of America 3Health News:Blue Cross Blue Shield of Michigan-owned DenteMax Acquired by Dental Network of America 4Health News:Blue Cross Blue Shield of Michigan-owned DenteMax Acquired by Dental Network of America 5
Used for traversing and exploring urethral strictures. The malleable tip can be shaped to desired configuration. The proximal end is threaded to attach to standard followers. Supplied sterile in peel...
Used to dilate the male or female urethra to treat stricture disease. Supplied sterile in peel-open packages. Intended for one-time use....
The balloon catheter is designed to pass over a previously placed .015 inch diameter wire guide included. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Medicine Products: